Targeted Oncology
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
Hamilton EP, Jeselsohn RM, Vahdat LT, Hurvitz SA.
In this review, the authors describe the unique mechanisms of action of PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degraders, a new class of drugs. The data underscore the potential for these PROTAC estrogen receptor degraders to offer a new backbone therapy in breast cancer.
Previous Article
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
